Welireg for Renal Cell Carcinoma: every route to paying for it

The routes, in order

1. 1

   Why this drug and this condition are paired

   (VHL) disease for treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), not requiring ...

   From the Indications and Usage text of the drug's FDA label. A label naming a condition is not a statement that the drug is approved, effective or covered for you.

   Label on openFDA, read 2026-11-10 · receipt

2. 2

   Medicare Part D: the yearly out-of-pocket threshold

   Found in our data
   CMS prints the Part D out-of-pocket threshold as $2,400 in 2027 ($2,100 in 2026).

   A benefit parameter of the standard Part D benefit. It applies to covered drugs under plan rules and is not a prediction of what you will pay. Your plan's formulary decides whether this drug is covered: check a formulary.

   CMS Table V-2, read 2026-11-08

3. 3

   Medicare negotiated price

   Not found in our data
   This drug is not in the CMS negotiated-price file we hold.
4. 4

   Manufacturer and foundation programs

   Found in our data
   • Merck Patient Assistance Program receipt status not recorded

   A status is what the program's page says about taking applications, not whether you qualify. Each program has its own eligibility rules.

5. 5

   Charitable funds for Renal Cell Carcinoma

   Found in our data
   We hold 4 funds for Renal Cell Carcinoma: 1 open and 3 not open, read 2026-11-08. Open: Renal Cell Carcinoma - Medicare Access from HealthWell Foundation.

   Every fund, with its award level, insurance supported and source, is on the Renal Cell Carcinoma page. A fund pays for a condition's costs, not necessarily this drug.

6. 6

   Clinical trial access

   Not found in our data
   We hold no trial listing for this ingredient.

Questions